TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
企業コードTMDX
会社名Transmedics Group Inc
上場日May 02, 2019
設立日2018
最高経営責任者「CEO」Dr. Waleed H. Hassanein, M.D.
従業員数728
証券種類Ordinary Share
決算期末May 02
本社所在地200 Minuteman Road
都市ANDOVER
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号01810
電話番号19785520900
ウェブサイトhttps://www.transmedics.com/
企業コードTMDX
上場日May 02, 2019
設立日2018
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし